3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
11
Cyclophosphamide
8
Gemcitabine
7
Cisplatin
7
tislelizumab
5
Docetaxel
5
Nivolumab
4
Injections
4
spartalizumab
3
regorafenib
3
Trastuzumab
3
Oncolytic Virotherapy
3
Irinotecan
3
Filgrastim
3
Drug Therapy
3
Doxorubicin
3
Carboplatin
3
Bortezomib
3
tazemetostat
2
pazopanib
2
liposomal doxorubicin
2
ganitumab
2
conatumumab
2
belinostat
2
Temozolomide
2
Taxes
2
Tamoxifen
2
Sorafenib
2
Riluzole
2
Radiotherapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Clinical Trials, Phase II as Topic
×
Thoracic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled